Gentian Diagnostics ASA

Report Publication Announcement • Aug 21, 2020

2nd quarter and first half 2020 report

2nd quarter and first half 2020 report

Moss, 21.08.20

Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include:

* Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19

* Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis

* Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN

* Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test

* New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay

Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.

For further information, please contact:

Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525